Article Text

Download PDFPDF
New evidence in hypertension and hyperlipidaemia
  1. N Chapman
  1. Correspondence to:
    Dr Neil Chapman
    St Mary’s Hospital, London W2 1NY, UK;


The benefits of blood pressure lowering on the risk of cardiovascular disease are seen with all commonly used classes of antihypertensive drugs. Although different drug classes may have different effects on cause specific outcomes (such as myocardial infarction or stroke), no differences are observed between their overall effects on combined major cardiovascular end points. The choice of first line antihypertensive drug is therefore likely to be of less importance than the use of any effective drug, particularly since the majority of patients will need two or more agents to achieve blood pressure goals. Recent trials have provided good evidence that lowering cholesterol with statins reduces the risk of cardiovascular events in “high risk” patients, irrespective of initial cholesterol concentrations. The benefits of both blood pressure lowering and lipid lowering treatment appear to be proportional to the extent of the reduction of blood pressure and lipids achieved.

  • hypertension
  • hyperlipidaemia
  • blood pressure
  • coronary heart disease
  • cholesterol
  • ACE, angiotensin converting enzyme
  • ALLHAT, antihypertensive and lipid-lowering treatment to prevent heart attack trial
  • ARB, angiotensin receptor blocker
  • ASCOT-LLA, Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm
  • BPLTTC, blood pressure lowering treatment trialists’ collaboration
  • CHD, coronary heart disease
  • HPS, heart protection study
  • IDNT, irbesartan diabetic nephropathy trial
  • LDL, low density lipoprotein
  • LIFE, losartan intervention for endpoint reduction in hypertension
  • PROSPER, pravastatin in elderly individuals at risk of vascular disease
  • RENAAL, reduction of end points in NIDDM with the angiotensin II antagonist losartan
  • SCOPE, study on cognition and prognosis in the elderly

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.